Evidence map›Paper›PMID 32508652›Full record

ArticleFrontiers in pharmacology2020

Yong Yang, Tian Yu, Huan Tang, Zhihui Ren, Qianwen Li, Juan Jia, Hongyu Chen, Jun Fu, Shengchen Ding, Qiang Hao and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. 7-Hydroxyflavone Mitigates OsteoporosisCurrent topics in medicinal chemistry · 2025
    Article
  8. Article
  9. Natural Bio-Compounds fromAntioxidants (Basel, Switzerland) · 2023
    Review
  10. Review
  11. Frontiers in immunology · 2023
    Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Yong YangSchool of Pharmaceutical Sciences, Jilin University, Changchun, China.
Tian YuSchool of Pharmaceutical Sciences, Jilin University, Changchun, China.
Huan TangSchool of Pharmaceutical Sciences, Jilin University, Changchun, China.
Zhihui RenSchool of Pharmaceutical Sciences, Jilin University, Changchun, China.
Qianwen LiSchool of Pharmaceutical Sciences, Jilin University, Changchun, China.
Juan JiaSchool of Pharmaceutical Sciences, Jilin University, Changchun, China.
Hongyu ChenSchool of Pharmaceutical Sciences, Jilin University, Changchun, China.
Jun FuSchool of Pharmaceutical Sciences, Jilin University, Changchun, China.
Shengchen DingSchool of Pharmaceutical Sciences, Jilin University, Changchun, China.
Qiang HaoSchool of Pharmaceutical Sciences, Jilin University, Changchun, China.
Dan XuSchool of Pharmaceutical Sciences, Jilin University, Changchun, China.
Liping SongSchool of Pharmaceutical Sciences, Jilin University, Changchun, China.
Bo SunSchool of Pharmaceutical Sciences, Jilin University, Changchun, China.
Fei SunSchool of Pharmaceutical Sciences, Jilin University, Changchun, China.
Jin PeiSchool of Pharmaceutical Sciences, Jilin University, Changchun, China.
Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune modulation has been recognized as an effective anti-osteoporosis strategy since the pivotal role of the RANK/RANKL/OPG signaling in bone metabolism and remodeling was discovered. To investigate the potential preventive and/or therapeutic effects of immune modulator protein Ling Zhi-8 (LZ-8) on osteoporosis, the osteoporosis animal model was established in Wistar rats by intramuscular injection of dexamethasone (DEX), namely glucocorticoids-induced osteoporosis (GIOP) rat model. To investigate the potential preventive effect of rLZ-8 on GIOP, we co-treated the rats with DEX and rLZ-8 intraperitoneally during the GIOP modeling stage and analyze the bone mass measured by bone mineral content (BMC) and bone mineral density (BMD), as well as levels of phosphorus (Pi), calcium (Ca

Indexed as

dexamethasoneGanoderma lucidumglucocorticoids-induced osteoporosis (GIOP)osteoporosisrLZ-8

Identifiers

PMID32508652
PMCPMC7248554
OpenAlexW3027056905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.